Improving the accuracy of cancer detection

Improving the accuracy of cancer detection

An innovative cancer diagnostic device developed by Manchester-based Zilico helps to improve accuracy in detecting cervical disease.

Find your nearest AHSN

Coordinates
By Zilico

Overview

An innovative cancer diagnostic device developed by Manchester-based Zilico helps to improve accuracy in detecting cervical disease.

Zilico has developed its patented Electrical Impedance Spectroscopy (EIS) into a platform technology for cancer diagnosis.

The ZedScan device uses EIS to differentiate normal, precancerous and cancerous tissue by measuring the electrical properties of the cervical epithelial cells. ZedScan guides a colposcopist to areas that need to be biopsied, when used with standard colposcopy.

More patients with cervical disease are detected; and those who test negative for disease can confidently be released back to routine cervical screening.

The initial focus of the company has been to improve the detection of cervical cancer and oral cancer and the product is in use in many trusts across the UK and internationally. The company also plans to apply the same approach to oesophageal, anal, vaginal and vulva cancers.  https://zilico.co.uk/       

Zilico was founded in 2006 following a successful collaboration between the University of Sheffield and Sheffield Teaching Hospitals NHS Foundation Trust, to develop a more accurate means of diagnosis for cervical intraepithelial neoplasia

How did the Innovation Exchange help?

Zilico is part of the Digital North Accelerator Programme. Four Academic Health Science Networks (AHSNs) are working together to help digital SMEs increase spread and adoption of their innovations across the whole of the north of England. Yorkshire & Humber AHSN, Health Innovation Manchester, Innovation Agency (AHSN for the North West Coast) and AHSN North East and North Cumbria